These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 21536860)

  • 1. Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.
    Salles G; de Jong D; Xie W; Rosenwald A; Chhanabhai M; Gaulard P; Klapper W; Calaminici M; Sander B; Thorns C; Campo E; Molina T; Lee A; Pfreundschuh M; Horning S; Lister A; Sehn LH; Raemaekers J; Hagenbeek A; Gascoyne RD; Weller E
    Blood; 2011 Jun; 117(26):7070-8. PubMed ID: 21536860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.
    Tzankov A; Leu N; Muenst S; Juskevicius D; Klingbiel D; Mamot C; Dirnhofer S
    J Hematol Oncol; 2015 Jun; 8():70. PubMed ID: 26071053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab.
    Akyurek N; Uner A; Benekli M; Barista I
    Cancer; 2012 Sep; 118(17):4173-83. PubMed ID: 22213394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
    Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
    J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
    Frei E; Visco C; Xu-Monette ZY; Dirnhofer S; Dybkær K; Orazi A; Bhagat G; Hsi ED; van Krieken JH; Ponzoni M; Go RS; Piris MA; Møller MB; Young KH; Tzankov A
    J Clin Pathol; 2013 Nov; 66(11):956-61. PubMed ID: 23775435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.
    Ott G; Ziepert M; Klapper W; Horn H; Szczepanowski M; Bernd HW; Thorns C; Feller AC; Lenze D; Hummel M; Stein H; Müller-Hermelink HK; Frank M; Hansmann ML; Barth TF; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Loeffler M; Rosenwald A
    Blood; 2010 Dec; 116(23):4916-25. PubMed ID: 20736456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
    Ennishi D; Yokoyama M; Terui Y; Asai H; Sakajiri S; Mishima Y; Takahashi S; Komatsu H; Ikeda K; Takeuchi K; Tanimoto M; Hatake K
    Ann Oncol; 2009 Mar; 20(3):526-33. PubMed ID: 19074749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
    Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
    Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI).
    Advani RH; Chen H; Habermann TM; Morrison VA; Weller EA; Fisher RI; Peterson BA; Gascoyne RD; Horning SJ; ; ;
    Br J Haematol; 2010 Oct; 151(2):143-51. PubMed ID: 20735398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
    Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
    Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
    Visco C; Li Y; Xu-Monette ZY; Miranda RN; Green TM; Li Y; Tzankov A; Wen W; Liu WM; Kahl BS; d'Amore ES; Montes-Moreno S; Dybkær K; Chiu A; Tam W; Orazi A; Zu Y; Bhagat G; Winter JN; Wang HY; O'Neill S; Dunphy CH; Hsi ED; Zhao XF; Go RS; Choi WW; Zhou F; Czader M; Tong J; Zhao X; van Krieken JH; Huang Q; Ai W; Etzell J; Ponzoni M; Ferreri AJ; Piris MA; Møller MB; Bueso-Ramos CE; Medeiros LJ; Wu L; Young KH
    Leukemia; 2012 Sep; 26(9):2103-13. PubMed ID: 22437443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of immunohistochemistry-based markers and algorithms in immunochemotherapy-treated diffuse large B cell lymphoma patients.
    Culpin RE; Sieniawski M; Angus B; Menon GK; Proctor SJ; Milne P; McCabe K; Mainou-Fowler T
    Histopathology; 2013 Dec; 63(6):788-801. PubMed ID: 24117687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
    Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
    J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy.
    Niitsu N; Tamaru J; Yoshino T; Nakamura N; Nakamura S; Ohshima K; Nakamine H; Okamoto M
    Ann Hematol; 2011 Feb; 90(2):185-92. PubMed ID: 20809421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Significance of
    Rosenwald A; Bens S; Advani R; Barrans S; Copie-Bergman C; Elsensohn MH; Natkunam Y; Calaminici M; Sander B; Baia M; Smith A; Painter D; Pham L; Zhao S; Ziepert M; Jordanova ES; Molina TJ; Kersten MJ; Kimby E; Klapper W; Raemaekers J; Schmitz N; Jardin F; Stevens WBC; Hoster E; Hagenbeek A; Gribben JG; Siebert R; Gascoyne RD; Scott DW; Gaulard P; Salles G; Burton C; de Jong D; Sehn LH; Maucort-Boulch D
    J Clin Oncol; 2019 Dec; 37(35):3359-3368. PubMed ID: 31498031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy.
    Hong J; Park S; Park J; Jang SJ; Ahn HK; Sym SJ; Cho EK; Shin DB; Lee JH
    Ann Hematol; 2012 Dec; 91(12):1897-906. PubMed ID: 22864685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real world data on young patients with high-risk diffuse large B-cell lymphoma treated with R-CHOP or R-CHOEP - MYC, BCL2 and BCL6 as prognostic biomarkers.
    Pedersen MØ; Gang AO; Brown P; Pedersen M; Knudsen H; Nielsen SL; Poulsen T; Wirenfeldt Klausen T; Høgdall E; Nørgaard P
    PLoS One; 2017; 12(10):e0186983. PubMed ID: 29088292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
    Ennishi D; Takeuchi K; Yokoyama M; Asai H; Mishima Y; Terui Y; Takahashi S; Komatsu H; Ikeda K; Yamaguchi M; Suzuki R; Tanimoto M; Hatake K
    Ann Oncol; 2008 Nov; 19(11):1921-6. PubMed ID: 18573805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.